Seeking Alpha 11/19
The company has the backing of most of the organizations and parents for the early approval of the drug. Based on the medical need in this area and the social pressure, FDA may want to speed up the process of bringing the drug in the market.
Sarepta has a wonderful drug in its pipeline, which can dominate the market for years. Unlike many other drugs, Eteplirsen has support from the public who want this drug to be in the market. It has shown phenomenal results and may force the FDA to approve the drug without phase III trials. Regardless of early approval, the stock will continue to move up in the short and medium term. However, if the early approval is granted - the stock will move up rapidly. In addition, it is extremely unlikely that the company will face competition any time soon. I remain particularly optimistic and confident that Sarepta will provide massive returns to investors.
True. Alpha articles aren't worth much. It's a good thing SRPT has the goods and doesn't need help from journalists. If anything financial journalists have been behind the curve on this one. Thanks to the parents of the DMD boys for bringing this to our atention.